" class="no-js "lang="en-US"> Catherine Martre - Medtech Alert
Sunday, October 19, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Catherine Martre

Catherine Martre

About Catherine Martre

Multicultural and business-oriented executive with 25 years of experience in Biotech and Pharma companies. Broad and international experience in strategic and business positions

Strategic and Operational skills applied to leadership positions in Business Strategy, Management, Business Development, Commercial Operations, Market Access

Related Story

Fundraising

 Meletios Therapeutics Raises €3.8 Million for the Development of a New Generation of Antiviral Treatments | Pharmtech Focus

Meletios Therapeutics Raises €3.8 Million for the Development of a New Generation of Antiviral Treatments

August 31 2021

Meletios Therapeutics, a French biotechnology company specialized in the research and development of next-generation antiviral […]